Bronchiectasis News and Research

RSS

Bronchiectasis is a condition in which the lung’s airways (bronchi) are dilated, causing an accumulation of mucus. This, in turn, makes the patient more vulnerable to infection, which can cause permanent damage. Most affected patients are middle-aged.

Chronic suppurative lung disease: an interview with Dr Robyn Marsh

Chronic suppurative lung disease, or CSLD, is used to describe a range of lung diseases characterised by a chronic wet cough and progressive lung damage. We are interested in the non-cystic fibrosis forms of the disease with a focus on bronchiectasis – the severe form of CSLD.

26 Nov 2012

Aradigm’s Lipoquin provides full protection in murine models of pneumonic plague

Scientists from the UK Defence Science and Technology Laboratory (Dstl) report, in a preliminary study, that they have demonstrated that a single dose of Aradigm Corporation's liposomal ciprofloxacin formulation Lipoquin administered 24 hours after exposure to a lethal dose of the bacterium Yersinia pestis provided full protection in a murine model of pneumonic plague.

20 Nov 2012

Pediatric lower respiratory illness continues after hospital discharge

One-third of children hospitalized with severe lower respiratory illness have chronic moist cough a year after discharge, research shows.

1 Oct 2012

Promising new treatment for bronchiectasis

Researchers have identified a promising new treatment for non-cystic fibrosis bronchiectasis, a long-term lung disorder which causes persistent coughing and breathlessness. The results, published in The Lancet, could represent an important advance in the treatment of this debilitating disease, for which very few evidence-based treatments are currently available.

17 Aug 2012

Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases

Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.

17 Aug 2012

OrPro to advance development of ORP-100 for treatment of cystic fibrosis

OrPro Therapeutics, Inc. today announced that the company has been awarded a National Heart, Lung and Blood Institute Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

31 Jul 2012

ICS may prevent parapneumonic effusion in patients with CAP

Prior treatment with inhaled corticosteroids in patients with respiratory disorders who develop community acquired pneumonia (CAP) is associated with a lower incidence and severity of parapneumonic effusion, according to a new study from researchers in Spain.

24 May 2012

Aradigm first quarter total revenue increases to $0.3 million

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2012.

11 May 2012

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

Aradigm Corporation today announced that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of Pulmaquin (dual release ciprofloxacin for inhalation) in non-cystic fibrosis bronchiectasis (BE) has been cleared by the U.S. Food and Drug Administration.

12 Mar 2012

COPDF announces expansion of Bronchiectasis Research Registry

The COPD Foundation (COPDF) today announced expansion of its Bronchiectasis Research Registry to include patients with Nontuberculous Mycobacteria (NTM), an often misdiagnosed orphan disease that can cause severe lung infections that mimic tuberculosis when certain individuals are exposed to soil and water.

12 Jan 2012

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

Pharmaceutical company Pharmaxis today announced the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add-on therapy to best standard of care."

24 Oct 2011

Aradigm announces two ciprofloxacin Phase 2b study data on non-CF bronchiectasis

Aradigm Corporation today announced it is presenting data on September 26, 2011, from its Phase 2b studies at the ERS Annual Congress in Amsterdam, Netherlands. The two podium presentations review the results from the Company's two clinical trials of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis (BE) patients.

22 Sep 2011

AHRQ finds more rural emergency department visits among low-income adults

Low-income adults ages 18 to 64 accounted for 56 percent of the 8 million visits made to rural hospital emergency departments in 2008, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

17 Jun 2011

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Aradigm Corporation today announced positive top line data from its recently concluded Phase 2b study (Once-Daily Respiratory Bronchiectasis Inhalation Treatment - ORBIT-1) with Aradigm's ciprofloxacin for inhalation (CFI, ARD-3100, LipoquinTM) in patients with non-cystic fibrosis bronchiectasis (BE).

16 Jun 2011

FDA grants orphan drug designation for Aradigm's ciprofloxacin to manage bronchiectasis

Aradigm Corporation today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for ciprofloxacin for inhalation for the management of bronchiectasis (BE).

6 Jun 2011

Aradigm first quarter total revenue decreases to $0.2 million

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2011.

12 May 2011

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010.

24 Mar 2011

Enrollment complete in Aradigm's inhaled ciprofloxacin Phase 2b study in non-cystic fibrosis bronchiectasis

Aradigm Corporation announced the last patient was enrolled in a Phase 2b study designed to evaluate the Company's inhaled liposomal ciprofloxacin (CFI, ARD-3100) in patients with non-cystic fibrosis bronchiectasis (BE), a severe progressive respiratory disease for which there is currently no approved treatment in the U.S.

23 Mar 2011

FDA clears Insmed IND for ARIKACE Phase 3 clinical trial in nontuberculous mycobacteria lung infections

Insmed Incorporated, a biopharmaceutical company, announced today that the Company's Investigational New Drug Application (IND) to conduct a pivotal Phase 3 clinical trial of ARIKACE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung infections has been cleared by the U.S. Food and Drug Administration (FDA).

21 Mar 2011

Kamada reports positive interim results from Alpha-Antitrypsin Phase 2-3 trial to treat Alpha-1 deficiency

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it received the interim report of its phase 2-3 trial to treat Alpha-1 deficiency with its flag product, Alpha-Antitrypsin, delivered by inhalation.

14 Feb 2011